Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney  Kent Doi, Yoshifumi Suzuki, Akihide Nakao,

Slides:



Advertisements
Similar presentations
Volume 63, Issue 2, Pages (February 2003)
Advertisements

Inflammatory cytokines in acute renal failure
Volume 94, Issue 3, Pages (September 2018)
Comparison between adult and infant lung injury in a rabbit ischemia-reperfusion model  Wanshan Qiu, MD, Liang Zheng, MD, Haiyong Gu, MD, Duan Chen, MD,
Volume 64, Issue 5, Pages (November 2003)
Volume 67, Issue 5, Pages (May 2005)
Volume 85, Issue 2, Pages (January 2014)
Volume 85, Issue 3, Pages (March 2014)
Volume 60, Issue 3, Pages (September 2001)
Volume 68, Issue 6, Pages (December 2005)
Volume 88, Issue 3, Pages (September 2015)
Li-Wen Lai, Kim-Chong Yong, Yeong-Hau H. Lien  Kidney International 
Bax and Bak have critical roles in ischemic acute kidney injury in global and proximal tubule–specific knockout mouse models  Qingqing Wei, Guie Dong,
The Case ∣ Acute renal failure and anemia
Volume 65, Issue 2, Pages (February 2004)
Volume 64, Issue 5, Pages (November 2003)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Volume 67, Issue 5, Pages (May 2005)
Volume 58, Issue 2, Pages (August 2000)
Volume 75, Issue 3, Pages (February 2009)
Volume 61, Issue 5, Pages (May 2002)
Volume 86, Issue 2, Pages (August 2014)
Genistein protects the kidney from cisplatin-induced injury
Volume 75, Issue 2, Pages (January 2009)
Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis  Hua Liu, Radhakrishna Baliga  Kidney International 
Volume 73, Issue 5, Pages (March 2008)
Volume 64, Issue 1, Pages (July 2003)
Volume 60, Issue 4, Pages (October 2001)
Volume 81, Issue 4, Pages (February 2012)
Volume 67, Issue 6, Pages (June 2005)
Decreased renal ischemia–reperfusion injury by IL-16 inactivation
Volume 79, Issue 1, Pages (January 2011)
Volume 64, Issue 5, Pages (November 2003)
Richard A. Zager, Ali C.M. Johnson, Sherry Y. Hanson 
Volume 89, Issue 2, Pages (February 2016)
Ischemic and non-ischemic acute kidney injury cause hepatic damage
Volume 66, Issue 6, Pages (December 2004)
Volume 60, Issue 6, Pages (December 2001)
Volume 83, Issue 3, Pages (March 2013)
Kenji Kasuno, Hajime Nakamura, Takahiko Ono, Eri Muso, Junji Yodoi 
Deletion of the epidermal growth factor receptor in renal proximal tubule epithelial cells delays recovery from acute kidney injury  Jianchun Chen, Jian-Kang.
Volume 54, Issue 3, Pages (September 1998)
Volume 65, Issue 3, Pages (March 2004)
Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin- induced acute kidney injury  K. Negishi, E. Noiri, R. Maeda, D.
Volume 62, Issue 5, Pages (November 2002)
Volume 63, Issue 2, Pages (February 2003)
Volume 85, Issue 1, Pages (January 2014)
Volume 73, Issue 11, Pages (June 2008)
Resistance to ischemic acute renal failure in the Brown Norway rat: A new model to study cytoprotection  David P. Basile, Deborah Donohoe, X.I.A. Cao,
Volume 56, Issue 3, Pages (September 1999)
Volume 55, Issue 6, Pages (June 1999)
Volume 85, Issue 3, Pages (March 2014)
Volume 60, Issue 6, Pages (December 2001)
Volume 68, Issue 2, Pages (August 2005)
Volume 85, Issue 4, Pages (April 2014)
Volume 76, Issue 7, Pages (October 2009)
Volume 75, Issue 5, Pages (March 2009)
Induction of heat shock protein 70 inhibits ischemic renal injury
Volume 65, Issue 6, Pages (June 2004)
Volume 60, Issue 6, Pages (December 2001)
Volume 67, Issue 4, Pages (April 2005)
Volume 64, Issue 3, Pages (September 2003)
Ganesan Ramesh, W. Brian Reeves  Kidney International 
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
Volume 80, Issue 2, Pages (July 2011)
Volume 58, Issue 5, Pages (November 2000)
Volume 95, Issue 5, Pages (May 2019)
A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia–reperfusion injury  L.-W. Lai, K.-C. Yong,
Volume 85, Issue 1, Pages (January 2014)
Volume 54, Issue 2, Pages (August 1998)
Presentation transcript:

Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney  Kent Doi, Yoshifumi Suzuki, Akihide Nakao, Toshiro Fujita, Eisei Noiri  Kidney International  Volume 65, Issue 5, Pages 1714-1723 (May 2004) DOI: 10.1111/j.1523-1755.2004.00567.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Blood urea nitrogen (BUN) (A), serum creatinine (Cr) (B) in rats subjected to 45-minute ischemia 24hours after surgery. Ischemia, control ischemia group; Edaravone, edaravone-treated groups; DMTU, dimethylthiourea-treated group; Sham, sham-operated group. *P < 0.05 versus control ischemia group; **P < 0.01 versus control ischemia group. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Time-course of serum creatinine (Cr) showing the continuous protective effect of edaravone. All the animals treated by edaravone at the doses of 5mg/kg and 10mg/kg and by dimethylthiourea (DMTU) survived for 72hours after surgery. However, only three (33.3%) of nine rats in the control ischemia group and three (50%) of six rats treated by edaravone at the dose of 1mg/kg survived for 72hours after surgery. The analysis was performed only on animals that survived at the examination of renal function. Symbols are: (•) control ischemia; (▪) edaravone 1mg/kg; (○) edaravone 5mg/kg; (□) edaravone 10mg/kg; and (▴) DMTU. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Histologic findings. Findings stained with hematoxylin-eosin (A), fluorescence microscopy detecting reactive oxygen species (ROS) by dichlorodihydrofluorescein (CM-H2DCFDA) (B), immunohistochemistry using antibody to 4-hydroxy-2-hexenal (HHE)-modified proteins (C), and histologic scoring of the intensity of ischemic acute renal failure (D). ATN, acute tubular necrosis; sham, sham-operated group; ischemia, control ischemia group; edaravone, edaravone-treated group. *P < 0.05 versus control ischemia; **P < 0.01 versus control ischemia. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Histologic findings. Findings stained with hematoxylin-eosin (A), fluorescence microscopy detecting reactive oxygen species (ROS) by dichlorodihydrofluorescein (CM-H2DCFDA) (B), immunohistochemistry using antibody to 4-hydroxy-2-hexenal (HHE)-modified proteins (C), and histologic scoring of the intensity of ischemic acute renal failure (D). ATN, acute tubular necrosis; sham, sham-operated group; ischemia, control ischemia group; edaravone, edaravone-treated group. *P < 0.05 versus control ischemia; **P < 0.01 versus control ischemia. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Western analysis of 4-hydroxy-2-hexenal (HHE)-modified protein expression. Sham, sham-operated group; ischemia, control ischemia group; Edaravone, edaravone-treated group. Histogram demonstrates the relative density of bands compared with alpha-tubulin (N = 3). Representative image is demonstrated in upper panel. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Measurement of intracellular reactive oxygen species (ROS) production in human renal proximal tubular cells (HKC-8) using the fluorogenic probe of intracellular ROS production, dichlorodihydrofluorescein (CM-H2DCFDA), in vitro. Fluorescence intensity (relative unit) was measured 60 minutes after exposure to H2O2 at the concentration of 0.5mmol/L. HKC-8 cells were incubated with edaravone at the concentration of 10−5 mol/L and 10−4 mol/L. *P < 0.05 versus control. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 6 Chronological analysis of intracellular reactive oxygen species (ROS) production in human renal proximal tubular cells (HKC-8) by dichlorodihydrofluorescein (CM-H2DCFDA) in vitro. Fluorescence intensity (relative unit) was measured in six independent wells in a 96-well microplate. *P < 0.005 versus control. Symbols are: (○) H2O2 0.5mmol/L; (•) edaravone 10−4 mol/L + H2O2 0.5mmol/L. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 7 Cell viability assay with Alamar blue. Human renal proximal tubular cells (HKC-8) loaded with hydrogen peroxide at the concentration of 0.5mmol/L were examined. *P < 0.05 versus control. Symbols are: (○) H2O2 0.5mmol/L; (•) edaravone 10−4 mol/L + H2O2 0.5mmol/L; (▪) edaravone 10−5 mol/L + H2O2 0.5mmol/L. Kidney International 2004 65, 1714-1723DOI: (10.1111/j.1523-1755.2004.00567.x) Copyright © 2004 International Society of Nephrology Terms and Conditions